Lotus Pharmaceutical Overview
- Year Founded
-
1966
- Status
-
Public
- Employees
-
1,099
- Stock Symbol
-
1795
- Investments
-
2
- Share Price
-
$8.25
- (As of Tuesday Closing)
Lotus Pharmaceutical General Information
Description
Lotus Pharmaceutical Co Ltd is engaged in the healthcare sector. The only reportable segment of the company is the Pharmaceuticals business segment, which engages mainly in the research and development, manufacturing and sales of pharmaceutical products. It has its geographic presence in United States, South Korea, Taiwan and Others.
Contact Information
Website
www.lotuspharm.comCorporate Office
- 17th Floor, Number 277
- Song Ren Road, Xin Yi District
- Taipei City, 110
- Taiwan
Corporate Office
- 17th Floor, Number 277
- Song Ren Road, Xin Yi District
- Taipei City, 110
- Taiwan
Lotus Pharmaceutical Stock Performance
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $8.25 | $8.32 | $6.33 - $10.76 | $2.19B | 265M | 2.77M | $0.48 |
Lotus Pharmaceutical Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 2,781,789 | 2,622,245 | 2,311,067 | 1,093,010 |
| Revenue | 532,335 | 544,431 | 491,507 | 452,653 |
| EBITDA | 213,722 | 219,577 | 176,547 | 104,525 |
| Net Income | 126,180 | 131,810 | 101,466 | 50,220 |
| Total Assets | 1,064,698 | 1,073,665 | 962,460 | 766,448 |
| Total Debt | 327,914 | 377,011 | 290,699 | 230,693 |
Lotus Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lotus Pharmaceutical Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Lotus Pharmaceutical Patents
Lotus Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4374853-A1 | Solid formulation of enzalutamide | Pending | 22-Nov-2022 | ||
| EP-4302755-A1 | Palbociclib formulation containing an amino acid | Pending | 07-Jul-2022 | ||
| EP-4302832-A1 | Palbociclib formulation containing glucono delta lactone | Pending | 07-Jul-2022 | ||
| EP-4260848-A1 | Pharmaceutical composition for solid dosage form containing nilotinib and process for its preparation | Inactive | 11-Apr-2022 | ||
| EP-4159199-A1 | Combined formulation of mirabegron and solifenacin | Inactive | 29-Sep-2021 | A61K9/4808 |
Lotus Pharmaceutical Executive Team (4)
| Name | Title | Board Seat |
|---|---|---|
| Petar Vazharov MD | Chief Executive Officer & Board Member | |
| Eeling Chan | Chief Financial Officer |
Lotus Pharmaceutical Board Members (22)
| Name | Representing | Role | Since |
|---|---|---|---|
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member | ||
| Self | Board Member |
Lotus Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lotus Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lotus Pharmaceutical Investments & Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Teva Pharma (Thailand) Company | 06-Jun-2024 | Pharmaceuticals | |||
| Alvogen Korea | 15-Feb-2019 | Corporate | Pharmaceuticals |
Lotus Pharmaceutical ESG
Risk Overview
Risk Rating
Updated February, 03, 2024
36.79 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 16,009
Rank
Percentile
Pharmaceuticals
Industry
of 909
Rank
Percentile
Pharmaceuticals
Subindustry
of 446
Rank
Percentile
Lotus Pharmaceutical FAQs
-
When was Lotus Pharmaceutical founded?
Lotus Pharmaceutical was founded in 1966.
-
Who is the CEO of Lotus Pharmaceutical?
Petar Vazharov MD is the CEO of Lotus Pharmaceutical.
-
Where is Lotus Pharmaceutical headquartered?
Lotus Pharmaceutical is headquartered in Taipei City, Taiwan.
-
What is the size of Lotus Pharmaceutical?
Lotus Pharmaceutical has 1,099 total employees.
-
What industry is Lotus Pharmaceutical in?
Lotus Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Lotus Pharmaceutical a private or public company?
Lotus Pharmaceutical is a Public company.
-
What is Lotus Pharmaceutical’s stock symbol?
The ticker symbol for Lotus Pharmaceutical is 1795.
-
What is the current stock price of Lotus Pharmaceutical?
As of 01-Oct-2024 the stock price of Lotus Pharmaceutical is $8.25.
-
What is the current market cap of Lotus Pharmaceutical?
The current market capitalization of Lotus Pharmaceutical is $2.19B.
-
What is Lotus Pharmaceutical’s current revenue?
The trailing twelve month revenue for Lotus Pharmaceutical is $532M.
-
What is Lotus Pharmaceutical’s annual earnings per share (EPS)?
Lotus Pharmaceutical’s EPS for 12 months was $0.48.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
